Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Panmira Pharmaceuticals, a US-based small molecule pharmaceutical company, has appointed Hari Kumar as the new CEO.
Subscribe to our email newsletter
Previously, Hari Kumar served as chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira’s fibrosis program.
According to the company, the new CEO will take charge of the company’s inflammation portfolio, featuring CRTH2 program with AM211 as its lead candidate.
AM211 is said to have demonstrated functional inhibition of eosinophils over 24 hours following oral, once-daily dosing in phase I studies.
Panmira is focused on developing novel therapies for inflammatory diseases.